In a phase 3 trial, tolebrutinib, an oral Bruton’s tyrosine kinase inhibitor, significantly reduced the risk of sustained disability progression in patients with nonrelapsing secondary progressive multiple...
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
A phase 2 study evaluating the safety and efficacy of letrozole, abemaciclib, and metformin in treating estrogen receptor–positive recurrent endometrial cancer highlights promising outcomes in a select...
In the RUBY trial, dostarlimab combined with chemotherapy delayed quality of life deterioration across multiple domains in patients with advanced or recurrent endometrial cancer, particularly in those with...
A retrospective cohort study found that patients on GLP-1 agonists had a lower risk of periprosthetic joint infection but a higher risk of periprosthetic fractures following total knee arthroplasty.
A clinical trial found hysteroscopic resection may improve outcomes for progestin-resistant atypical hyperplasia or grade 1 endometrial cancer in select patients. This study was presented at the Society of...
Pain following hand surgery was generally low and peaked on Days 1 and 3, with no significant influence from anxiety, catastrophizing, age, or gender—suggesting time-sensitive strategies are key for pain...
Explore how value-based care providers can navigate the clinical and financial impact of emerging therapies, biosimilars, and federal drug pricing reforms.
Patients who underwent laparoscopic hysterectomy alone were more likely to be readmitted within 60 days compared with those who also received sacrocolpopexy.
